Factor Xa Inhibition Reduces Coagulation Activity but Not Inflammation Among People With HIV: A Randomized Clinical Trial

Abstract Background Coagulation activity among persons with HIV is associated with end-organ disease risk, but the pathogenesis is not well characterized. We tested a hypothesis that hypercoagulation contributes to disease risk, in part, via upregulation of inflammation. Methods Treatment effects of edoxaban (30 mg), a direct factor Xa inhibitor, vs placebo were investigated in a randomized, double-blind crossover trial among participants with HIV and viral suppression and D-dimer levels ≥100 ng/mL. During each 4-month crossover period, blood measures of coagulation, inflammation, and immune activation were assessed. Analyses of change on edoxaban vs change on placebo used linear mixed models. Results Forty-four participants were randomized, and 40 completed at least 1 visit during each study period. The mean age was 49 years, and the CD4+ count was 739 cells/mm3. Edoxaban treatment led to declines in D-dimer (44%) and thrombin-antithrombin complex (26%) but did not lower inflammatory or immune activation measures. More bruising or bleeding events occurred during edoxaban (n = 28) than during placebo or no drug periods (n = 15). Conclusions The direct factor Xa inhibitor edoxaban led to a substantial reduction in coagulation but no effect on inflammation or immune activation. These results do not support that hypercoagulation contributes to ongoing inflammation during chronic antiretroviral therapy–treated HIV disease.

[1]  P. F. Kauff.  Group , 2000, Elegant Design.

[2]  S. Kent,et al.  Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial. , 2018, The lancet. HIV.

[3]  J. Cleland,et al.  Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease , 2018, The New England journal of medicine.

[4]  D. Jacobs,et al.  Inflammation-Related Morbidity and Mortality Among HIV-Positive Adults: How Extensive Is It? , 2017, Journal of acquired immune deficiency syndromes.

[5]  C. Schooling,et al.  Coagulation Factors and the Risk of Ischemic Heart Disease: A Mendelian Randomization Study , 2018, Circulation. Genomic and precision medicine.

[6]  A. Sher,et al.  Inflammatory monocytes expressing tissue factor drive SIV and HIV coagulopathy , 2017, Science Translational Medicine.

[7]  Jerome H. Kim,et al.  Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  J. Lundgren,et al.  Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy , 2016, PloS one.

[9]  B. Agan,et al.  D-Dimer Levels before HIV Seroconversion Remain Elevated Even after Viral Suppression and Are Associated with an Increased Risk of Non-AIDS Events , 2016, PloS one.

[10]  M. Lederman,et al.  CD8 T-Cell Expansion and Inflammation Linked to CMV Coinfection in ART-treated HIV Infection. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  C. Kahler,et al.  Elevated Soluble CD14 and Lower D-Dimer Are Associated With Cigarette Smoking and Heavy Episodic Alcohol Use in Persons Living With HIV , 2015, Journal of acquired immune deficiency syndromes.

[12]  H. Lane,et al.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. , 2015, The New England journal of medicine.

[13]  Blair H. Smith,et al.  Association between cognition and gene polymorphisms involved in thrombosis and haemostasis , 2015, AGE.

[14]  R. Paredes,et al.  Adjudicated Morbidity and Mortality Outcomes by Age among Individuals with HIV Infection on Suppressive Antiretroviral Therapy , 2014, PloS one.

[15]  N. Mackman,et al.  Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. , 2014, Blood.

[16]  J. Brooks,et al.  Frailty and Pre-Frailty in a Contemporary Cohort of HIV-Infected Adults. , 2014, The Journal of frailty & aging.

[17]  L. Kuller,et al.  HIV Replication Alters the Composition of Extrinsic Pathway Coagulation Factors and Increases Thrombin Generation , 2013, Journal of the American Heart Association.

[18]  Robert L. Bradford,et al.  Circulating Levels of Tissue Factor Microparticle Procoagulant Activity Are Reduced With Antiretroviral Therapy and Are Associated With Persistent Inflammation and Coagulation Activation Among HIV-Positive Patients , 2013, Journal of acquired immune deficiency syndromes.

[19]  D. Follmann,et al.  Enhanced effector function of CD8(+) T cells from healthy controls and HIV-infected patients occurs through thrombin activation of protease-activated receptor 1. , 2013, The Journal of infectious diseases.

[20]  D. Podzamczer,et al.  Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir , 2012, AIDS.

[21]  L. Kuller,et al.  Inflammation, Coagulation and Cardiovascular Disease in HIV-Infected Individuals , 2012, PloS one.

[22]  R. Ribeiro,et al.  Coagulation biomarkers predict disease progression in SIV-infected nonhuman primates. , 2012, Blood.

[23]  D. Jacobs,et al.  Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. , 2010, The Journal of infectious diseases.

[24]  M. Lederman,et al.  Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. , 2010, Blood.

[25]  P. Stein,et al.  Human Immunodeficiency Virus Infection and Risk of Venous Thromboembolism , 2008, The American journal of the medical sciences.

[26]  Lewis H Kuller,et al.  Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection , 2008, PLoS medicine.

[27]  T. Schacker.  The role of secondary lymphatic tissue in immune deficiency of HIV infection , 2008, AIDS.

[28]  M. Hollenberg,et al.  Role of protease‐activated receptors in inflammatory responses, innate and adaptive immunity , 2008, Journal of leukocyte biology.

[29]  M. Lederman,et al.  Microbial translocation is a cause of systemic immune activation in chronic HIV infection , 2006, Nature Medicine.

[30]  P. Ridker,et al.  Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms , 2005, Nature Reviews Drug Discovery.

[31]  C. Moertel,et al.  Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. , 1998, Blood.